Neuralstem ALS Clinical Trial Update

Author: Neuralstem
Published: 2011/02/10 - Updated: 2022/06/06
Contents: Summary - Definition - Introduction - Main - Related

Synopsis: Neuralstem reports the progress of ongoing Phase I human clinical trial of spinal cord stem cells in the treatment of Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease. We are greatly encouraged by the SMB's approval to advance the trial to the final three patients to receive complete lumbar injections," said Karl Johe, Ph.D., Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. The trial has progressed as expected, and we are deeply indebted to the patients and families who have taken part. While the trial evaluates only the safety of the cells and procedure, it includes exploratory endpoints, including attenuation of motor function loss, maintenance of respiratory capacity, and stabilization of patients along the ALS functional rating scale.

Introduction

Neuralstem, Inc. updated the progress of its ongoing Phase I human clinical trial of the company's spinal cord stem cells in the treatment of ALS (amyotrophic lateral sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia.

Main Digest

The company announced that, after reviewing the safety data from the first nine patients, the trial's Safety Monitoring Board has unanimously approved moving to the last group of ALS patients in this part of the safety trial. These next three patients, all of whom are ambulatory, will each receive ten injections, bilaterally, in the lumbar spinal cord. After this cohort, the FDA will review the trial data to date before approving it to move into the final cohort of patients, who will receive injections in the cervical region of the spinal cord.

"We are delighted that we've advanced to this final cohort of patients in the first part of the safety trial," commented Dr. Eva Feldman, PhD, MD, Principal Investigator of the trial and a consultant to Neuralstem. Dr. Feldman is Director of the A. Alfred Taubman Medical Research Institute and Director of Research of the ALS Clinic at the University of Michigan Health System. "We have been pleased with the smooth progress of the trial thus far, from non-ambulatory to ambulatory patients who have an earlier stage of the disease."

"We are greatly encouraged by the SMB's approval to advance the trial to the final three patients to receive full lumbar injections," said Karl Johe, PhD, Chief Scientific Officer and Chairman of Neuralstem's Board of Directors. "The trial has progressed as expected, and we are deeply indebted to the patients and families who have taken part."

About The Trial

The Phase I trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS, the first FDA-approved ALS stem cell trial, has been underway since January, 2010. The trial plans to enroll up to 18 ALS patients, who will be examined at regular intervals post-surgery.

All of the first six patients treated in the trial were non-ambulatory.

Of these, the first three received five injections each, unilaterally, in the lumbar region of the spinal cord.

The next three patients received ten injections each, bilaterally in the lumbar region.

All remaining trial patients are ambulatory, and therefore represent earlier stages of disease progression.

Of the ambulatory group, the first three patients received five injections each, unilaterally, in the lumbar region.

The next three, which have just been approved, will receive ten injections each, bilaterally, in the lumbar region.

After the required FDA approval, the final six patients in the trial will receive injections in the cervical region.

While the trial is evaluating only the safety of the cells and procedure, it includes exploratory endpoints including attenuation of motor function loss, maintenance of respiratory capacity, and stabilization of patients along the ALS functional rating scale.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in a FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, which has been rewarded Orphan Drug Status by the FDA.

In addition to ALS, the company is also targeting major central nervous system diseases, including traumatic spinal cord injury, ischemic spastic paraplegia, and Huntington's disease. The company has also submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Attribution/Source(s):

This quality-reviewed publication titled Neuralstem ALS Clinical Trial Update was selected for publishing by Disabled World's editors due to its relevance to the disability community. While the content may have been edited for style, clarity, or brevity, it was originally authored by Neuralstem and published 2011/02/10 (Edit Update: 2022/06/06). For further details or clarifications, you can contact Neuralstem directly at Neuralstem, Inc. Disabled World does not provide any warranties or endorsements related to this article.

Related Publications

Share This Information To:
𝕏.com Facebook Reddit

Page Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide news and information to people with disabilities, seniors, their family and carers. We'd love for you to follow and connect with us on social media!

Cite This Page (APA): Neuralstem. (2011, February 10 - Last revised: 2022, June 6). Neuralstem ALS Clinical Trial Update. Disabled World. Retrieved June 20, 2024 from www.disabled-world.com/medical/clinical-trials/als-trial.php

Permalink: <a href="https://www.disabled-world.com/medical/clinical-trials/als-trial.php">Neuralstem ALS Clinical Trial Update</a>: Neuralstem reports the progress of ongoing Phase I human clinical trial of spinal cord stem cells in the treatment of Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig's disease.

Disabled World provides general information only. Materials presented are never meant to substitute for qualified medical care. Any 3rd party offering or advertising does not constitute an endorsement.